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Allelic Loss at Drosophila Patched Gene Is Highly
Prevalent in Basal and Squamous Cell Carcinomas
of the Skin
Hadi Danaee1, Margaret R. Karagas2, Karl T. Kelsey1, Ann E. Perry3 and Heather H. Nelson4
The human homolog of the Drosophila Patched gene (PTCH), located at chromosome 9q22.3, is frequently
altered in both nevoid basal cell carcinoma syndrome, and sporadic basal cell carcinomas (BCCs). However,
alteration of the PTCH gene locus has been poorly studied in squamous cell carcinoma (SCC). We analyzed loss
of heterozygosity (LOH) at five markers in and around the PTCH gene in 276 keratinocyte tumors from a
population-based study in New Hampshire. We found a high prevalence of any 9q22.3 LOH in both BCC (75.5%)
and SCC (60.8%), with BCC being significantly more likely to have LOH than SCC (Po0.009). The PTCH gene was
specifically lost in 60% of BCC, and 50% of SCC tumors. Among SCC tumors, 9q22 LOH was significantly more
likely to occur in those who tend to burn (Po0.05), and this association was strongest for tumors that occurred
on sun-exposed areas of the body (Po0.04). Additionally, 9q22 LOH occurred more frequently in SCC tumors
associated with a history of severe sunburns (Po0.08). Thus, in our large, population-based sample, 9q22 loss,
including PTCH, was highly prevalent in both BCC and SCC. Overall, these data support the hypothesis that
PTCH loss is a common, early lesion for SCC and BCC.
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INTRODUCTION
Basal cell (BCCs) and squamous cell carcinomas (SCCs) are
the most common cancers among US Caucasians (ACS,
2002), and incidence is increasing at both low and high
altitudes (Karagas et al., 1999; Harris et al., 2001). Risk
factors for these cancers include fair skin, excess sun
exposure, immunosuppression, and exposure to other carcino-
gens such as arsenic and polyaromatic hydrocarbons (Scotto
et al., 1996). BCCs are the more common type of skin cancer,
and are characterized by slow growth, local invasion, and rare
metastasis (Preston and Stern, 1992; Quinn et al., 1994a). In
contrast, SCCs have a greater metastatic potential and are
responsible for the majority of non-melanoma skin cancer
deaths (Preston and Stern, 1992).
BCCs most often occur as sporadic tumors, but they also
develop in patients with the rare autosomal dominant
disorder nevoid basal cell carcinoma syndrome (Gorlin,
1995). The gene for this disorder has been cloned and
identified as the human homologue of the drosophila
segment polarity gene patched (PTCH) located on chromo-
some 9q22.3 (Gailani et al., 1992; Hahn et al., 1996; Johnson
et al., 1996). As with nevoid basal cell carcinoma syndrome
tumors, PTCH is frequently altered in sporadic BCCs
(reviewed in Bale and Yu, 2001), and these data support
the hypothesis that PTCH is a gatekeeper gene for the
development of BCC (Sidransky, 1996).
PTCH encodes a transmembrane protein that serves as the
receptor for sonic hedgehog (Shh) (Marigo et al., 1996; Stone
et al., 1996). Ptch represses hedgehog target gene expression
through its interaction with Smoothened (Smo), and this
repression is relieved when Shh binds Ptch, or after PTCH has
been inactivated through mutation. Ptch regulates its own
expression through a negative feedback loop and inactivating
mutations in PTCH lead to overexpression of mutant PTCH
mRNA in BCC tumors (reviewed in Bale and Yu, 2001).
Further, multiple genes in the SHH pathway have been
demonstrated to be inactivated in BCC (Reifenberger et al.,
1998).
Although PTCH loss clearly contributes to the genesis of
BCC, there is no established role for PTCH alteration in SCC.
Unlike BCC tumors, overexpression of PTCH mRNA is not a
common event in SCC or extracutaneous tumors (Eklund
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et al., 1998; Zhilan et al., 2003). LOH at chromosome 9q22.3
has been observed, but with imprecise estimates of the
prevalence of loss (Table 4). In total, 143 SCC tumors have
been investigated for LOH; the largest study contained 49
SCCs. These small sample sizes, from ethnically and
geographically diverse populations, have resulted in a wide
range of estimates for 9q loss (0–70%). Similarly, mutation in
SCC has been evaluated in only 64 tumors (30 in one study),
with mutation prevalence ranging from 0 to 15%.
PTCH alteration is a critical determinant of BCC. How-
ever, small studies of SCC have limited interpretability, and
an expanded investigation including population-based SCC
tumors is important in order to distinguish whether this gene
is critical to both BCC and SCC. Herein, we have performed
loss of heterozygosity (LOH) analysis on tumors from an
ongoing large epidemiologic study of keratinocyte cancers in
New Hampshire, to test the hypothesis that LOH events at
PTCH are histology specific.
RESULTS
A total of 276 tumors from 250 cases were informative for
loss using five markers on chromosome 9q22. Overall, there
was a high prevalence of any LOH on 9q22 in both SCC
(60.8%) and BCC (75.5%) (Table 1, Figure 1). BCC tumors
were 2 times more likely than SCC to have any loss on 9q22.3
(Po0.009). The PTCH gene was specifically lost in 50% of
SCC and 60% of BCC tumors. To estimate whether the extent
of LOH differed by histology, we calculated fractional allele
loss (number of lost markers/number of informative markers)
for each tumor, and there was no difference in this measure
by histology (data not shown). In addition, the prevalence of
LOH did not differ according to the amount of adjacent
normal tissue (68% LOH in the quartile with the fewest tumor
cells, and 62% LOH among tumors with less than 25%
normal tissue).
BCC and SCC were evaluated separately to identify epi-
demiologic determinates of PTCH LOH. For each variable,
a w2 or Wilcoxon’s rank-sum test was used to test whether
there was a significant difference in the prevalence of LOH
with exposures or traits (Table 2). For BCC, the prevalence
of LOH was constant across skin type groups. In addition,
there were no differences in the number of lifetime sunburns
for those with and without LOH, nor was histologic solar
elastosis, a measure of chronic photoexposure, associated
Table 1. 9q22.3 LOH in BCC and SCC of the skin
Marker Chromosome location1 BCC SCC P-value2
D9S15 69571447–69571598
Retain 67 (81.7%) 64 (81%)
LOH present 15 (18.3%) 15 (19%) 0.9
D9S196 93553591–93553855
Retain 17 (27.8%) 24 (46.1%)
LOH present 42 (72.2%) 28 (53.9%) 0.06
Ptch exon 1a3 95287716–95287944
Retain 24 (40%) 19 (50%)
LOH present 36 (60%) 19 (50%) 0.3
D9S176 99137859–99138032
Retain 57 (50.4%) 45 (57%)
LOH present 56 (49.6%) 34 (43%) 0.4
D9S53 104641192–104641317
Retain 59 (61.5%) 57 (74%)
LOH present 37 (38.5%) 20 (26%) 0.08
Any LOH4
Absent 37 (24.5%) 49 (39.2%)
Present 114 (75.5%) 76 (60.8%) 0.009
BCC, basal cell carcinoma; LOH, loss of heterozygosity; SCC, squamous cell carcinoma.
1bp location according to NCBI UniSTS database, for exon1a the gene start position is given.
2w2 test of independence for marker loss and tissue histology.
3Dinucleotide repeat IAJL (Louhelainen et al., 1998).
4Among those informative for at least one marker.
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with LOH. Considering these same variables and SCC
(Table 2), there were statistically significant differences in
LOH by skin type, with the prevalence of LOH significantly
lower among those who always tan (Po0.05), and a non-
significant trend for increased LOH with lifetime sunburns
(Po0.08).
Tumors were stratified by anatomic site, broadly grouped
into sun-exposed (head, neck, arms) and sun-protected (trunk
and legs). We tested whether the initial observation of
increased LOH in BCC versus SCC (Table 1) was similar
among anatomic site groupings (Figure 2). The strong
difference in LOH by histology (Po0.009, Table 1 and
Figure 2) was only evident on sun-protected but not sun-
exposed sites (Po0.002 vs Po0.2, Figure 2). We further
examined whether epidemiologic determinants of LOH
differed by anatomic site of the tumor (Table 3). All BCC
tumors on sun-protected sites had 9q22 LOH among those
who reported sunlamp use, compared to 76.7% among
non-users of sunlamps, and this difference was of border-
line statistical significance (P¼0.05). In addition, for SCC,
the association between increased LOH and tendency to
sunburn was only evident for tumors on sun-exposed areas of
the body (Po0.04).
DISCUSSION
Our data demonstrate that LOH in the PTCH region on
9q22 is a highly prevalent event in both BCC and SCC, with
BCC tumors having significantly more deletion events in
the PTCH region than SCC. Loss was highest in and around
the PTCH gene, suggesting that the gene itself is targeted for
alteration in both BCC and SCC. In addition, the detection of
LOH was not sensitive to the amount of pathologically
normal tissue, indicating that the tumor is homogeneous for
LOH. The frequency of loss observed for BCC is comparable
to what has been reported previously for tumors from
sporadic cases (Gailani et al., 1992; Quinn et al., 1995;
Hahn et al., 1996; Holmberg et al., 1996; Johnson et al.,
1996; Shen et al., 1999; Ling et al., 2001; Kim et al., 2002;
Asplund et al., 2005; Reifenberger et al., 2005). Prior studies
of SCC have reported a wide range of 9q22 LOH prevalence
(0–70%), likely due to the small number of tumors studied in
any given report (reviewed in Table 4). Here, in a large case
series, we found that 9q markers, including a PTCH -specific
marker, are lost in a high proportion of SCC (60%). Small
sample sizes can lead to imprecise estimates of true
population prevalence, and this may partly explain why our
results differ from those of the previous reports. In addition,
our study sampled from all treating physicians within a
geographically defined region, and our larger sample size
permitted us to examine tumors from sun-exposed and sun-
protected sites separately. It is possible that prior reports
represented populations with different traits and exposures
than our New Hampshire population (ie sun sensitivity),
that relate to the prevalence of LOH in SCC reported here.
In addition, by not relying on a tertiary care center for
the collection of cases we have not biased our sample by
the clinical phenotype of the tumors (ie aggressive or
invasive), which could also impact the prevalence of gene
deletion.
The epidemiologic design of our study allowed us to
examine how patient traits and exposures relate to 9q22 loss.
In BCC, LOH occurred independent of age, gender, skin
type, and sunburn history. However, for SCC, PTCH region
deletion was highest among those that burn and had a higher
number of lifetime sunburns. In contrast, the occurrence
of 9q22 LOH did not vary by measures of chronic
actinic exposure (ie extent of solar elastosis). This suggests
that indicators of acute, intense UV exposure, as occurs
with sunburning, may lead to 9q22 LOH in SCC tumors.
Sunburning also is consistent with the etiology of BCC, and
these data suggest that a subset of SCC may have a common
origin to BCC both in terms of exposure and early molecular
alterations.
Our observation of significant loss of 9q, including
the PTCH gene region, in SCC tumors suggests that 9q
or the PTCH gene itself is crucial to SCC development. This
is supported by in vitro work as mice heterozygous at the
PTCH locus develop SCC tumors following UV expo-
sure (Aszterbaum et al., 1999), as well as bladder carcino-
mas in response to nitrosamine exposure (Hamed et al.,
2004). However, nevoid basal cell carcinoma syndrome
patients are not reported to develop excess SCC tumors. As
chromosome 9q22 is dense with documented tumor sup-
pressor genes, including FANCC and XPA, it is possible that
it is one of these adjacent genes that are targeted for loss in
SCC. Additional research, possibly using fine mapping
techniques, is needed to resolve the question of deletions at
9q22 in SCC.
In BCC disease, it has been well demonstrated that
mutations in PTCH lead to overexpression of ptch mRNA,
and that two gene inactivation events normally occur. The
balance between PTCH, Shh, and Smo expression is essential











LOH prevalence and 95% CI 
0 20 40 60 80 100
SCC
BCC
Figure 1. Prevalence and 95% confidence interval for LOH at five markers
in SCC and BCC tumors.
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PTCH could lead to tumor formation. In the case of SCC, it is
plausible that there is no second mutation event at PTCH. A
similar scenario has been observed for bladder cancers,
where 9q22.3 appears targeted for genetic deletion (Cairns
et al., 1993; Simoneau et al., 1999, 2000; Kimura et al.,
2001; Wada et al., 2003), with little evidence for PTCH
mutation (Xie et al., 1997; McGarvey et al., 1998; Ohgaki
et al., 1999; Aboulkassim et al., 2003). Haploinsufficiency at
the PTCH locus has been proposed as contributing to bladder
carcinogenesis (Aboulkassim et al., 2003) and medulloblast-
omas (Wetmore et al., 2000; Zurawel et al., 2000), a model
that may also apply to SCC (Aszterbaum et al., 1999).
Recently, it has been reported that uniparental disomy is
a common mechanism of PTCH gene inactivation in BCC
(Teh et al., 2005). This is consistent with a two-hit mecha-
nism for ptch in BCC, with LOH occurring without a change
in genomic copy number. If this mechanism is unique to
BCC, and SCC tumors retain only a single 9q allele, it could
partially explain the lack of excess ptch RNA in SCC tumors.
In addition, BCC tumors from ptch heterozygote animals
have enhanced ptch promoter activity, whereas SCC tumors
do not (Aszterbaum et al., 1999), indicating that the feedback
loops for these two types of tumors substantially differ.
Table 2. Epidemiologic determinants of LOH in the ptch gene region
BCC SCC
9q retained 9q LOH P-value 9q retained 9q LOH P-value
Sex
Male 28 (28.3%) 71 (71.7%) 34 (38.6%) 54 (61.4%)
Female 9 (17.3%) 43 (82.7%) 0.1 15 (40.5%) 22 (59.5%) 0.8
Median age (years) 64 62 68 67
(range) (32 – 74) (29 – 73) 0.6 (39–74) (39–74) 0.7
Skin type1
Tans 4 (28.6%) 10 (71.4%) 10 (62.5%) 6 (37.5%)
Burns then tans 16 (23.2%) 53 (76.8%) 17 (29.8%) 40 (70.2%)
Severe burn 17 (25%) 51 (75.0%) 0.9 22 (43.1%) 29 (56.9%) 0.05
Painful sunburns2
0 11 (35.5%) 20 (64.5%) 20 (56.7%) 17 (43.3%)
1–3 6 (15%) 34 (85%) 12 (32.4%) 25 (67.6%)
4+ 20 (25%) 60 (75%) 0.1 16 (32.6%) 33 (67.4%) 0.08
Sunlamp use
No 32 (27.8%) 83 (72.2%) 43 (41.7%) 60 (58.3%)
Yes 5 (13.9%) 31 (86.1%) 0.09 6 (27.3%) 16 (72.7%) 0.2
Histologic solar elastosis
Minimal 1 (7.7%) 12 (92.3%) 0 1 (100%)
Moderate 11 (25.6%) 32 (74.4%) 6 (40%) 9 (60%)
Severe 16 (26.2%) 45 (73.8%) 0.3 38 (39.2%) 59 (60.8%) 0.7
BCC, basal cell carcinoma; LOH, loss of heterozygosity; SCC, squamous cell carcinoma.
1Skin response to first sun exposure in summer.
2Lifetime number of sunburns causing pain for 2 or more days.




















Figure 2. The prevalence of any 9q22 LOH in SCC and BCC, stratified by
anatomic site of the tumor.
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The data from this population-based study indicate that
PTCH alteration is not specific for BCC, and that loss of one
allele is common to both SCC and BCC. It is plausible that
SHH pathway deregulation is a necessary event for dysregu-
lated skin growths, as a high prevalence of PTCH alteration,
including LOH, has also been observed in trichoepitheliomas
(Vorechovsky et al., 1997; Matt et al., 2000) and sebaceous
nevi (Xin et al., 1999). Further characterization of the PTCH
Table 3. Anatomic site of tumor modifies the prevalence of LOH
Sun-exposed Sun-protected
BCC SCC BCC SCC
Skin type
Tans 7/10 (70%) 5/15 (33.3%) 3/4 (75%) 1/1 (100%)
Burns then tans 30/45 (66.7%) 37/53 (69.8%) 23/24 (95.8%) 2/3 (66.7%)
Severe burn 30/39 (76.9%) 22/37 (59.5%) 21/29 (72.4%) 6/13 (46.2%)
P-value 0.6 0.04 0.08 0.5
Painful sunburns
0 13/20 (65%) 15/30 (50%) 7/11 (63.6%) 1/6 (16.7%)
1–3 22/27 (81.5%) 21/32 (65.6%) 12/13 (92.3%) 4/5 (80%)
4+ 32/47 (68.1%) 28/42 (66.7%) 28/33 (84.9%) 4/6 (66.7%)
P-value 0.4 0.3 0.2 0.08
Sunlamp use
No 50/72 (69.4%) 52/90 (57.8%) 33/43 (76.7%) 7/12 (58.3%)
Yes 17/22 (77.3%) 12/15 (80%) 14/14 (100%) 3/6 (50%)
P-value 0.5 0.1 0.05 0.7
Histologic solar elastosis
Minimal 1/1 (100%) 1/1 (100%) 11/12 (91.7%) Not observed
Moderate 14/20 (70%) 6/10 (60%) 18/23 (78.3%) 3/5 (60%)
Severe 37/50 (74%) 53/85 (62.4%) 8/11 (72.7%) 4/10 (40%)
P-value 0.8 0.7 0.5 0.5
BCC, basal cell carcinoma; LOH, loss of heterozygosity; SCC, squamous cell carcinoma.
Table 4. 9q22 and PTCH alterations in cutaneous SCC
Reference Sample size 9q22 LOH (%) PTCH mutation (%) PTCH expression
Current study, Danaee et al. (2005) 130 62
Granga et al. (2003) 30 0
Ping et al. (2001) 20 15
Mortier et al. (2000) 27 70
He et al. (1999)1 21 0
Nagano et al. (1999) 8 50% (weak signal, IHC)
Eklund et al. (1998) 14 50 0 0% (n=6, RNA)
Ahmadian et al. (1998) 11 63
Holmberg et al (1996) 11 25
Quinn et al. (1994b) 49 33
Zaphiropoulos et al. (1994) 10 40
1Only one marker examined.
IHC, immunohistochemistry; LOH, loss of heterozygosity; SCC, squamous cell carcinoma.
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gene and Shh pathway in epithelial malignancies is needed
and may help illuminate the mechanism of histologic
divergence in keratinocyte cancers.
MATERIALS AND METHODS
Study population
Cases were selected from a statewide incidence survey of
dermatologists and pathology laboratories that identifies newly
diagnosed primary BCC and SCC in New Hampshire, in operation
since 1993 (Karagas et al., 1999). For the parent study, all cases of
invasive SCC, and a randomly selected group of BCC (roughly in
a 1:1 ratio to SCC cases) diagnosed between July 1, 1997 and March
31, 2000 were invited to participate in a detailed epidemiologic
study. A comprehensive pathology review was conducted by the
study dermatopathologist, including classification of tumor morpho-
logy, grade, associated actinic keratoses, degree of histologic solar
elastosis, and percent of tumor present in the tissue specimen.
Cases completed an administered questionnaire to obtain
information on demographic traits. Exposure variables included in
the current analysis are as follows: (1) skin type, classified according
to the participant’s recollection of skin response to first sun exposure
at the beginning of summer, (2) number of lifetime painful sunburns
(painful for 2 or more days), and (3) anatomic site of tumor classified
as sun-exposed (head, neck, arms) or sun-protected (trunk and legs).
A subset of cases was analyzed in the current study. Two hundred
and eighty-two tumors from 262 cases were included in the current
analysis. Six cases were not informative at any of the tested loci,
leaving a total of 276 tumors from 250 cases. For 16 cases, we
investigated multiple tumors (ranging from 2 to 5).
Each tumor was scored by the study pathologist regarding the
amount of non-tumorous tissue present in the specimen (0–25,
25–50, 50–75, 475%), and LOH was subsequently evaluated in
each of these categories to ensure results were not biased by the
presence of non-tumorous tissue.
All elements of the research design were approved by the
Dartmouth Medical School and Harvard School of Public Health
Institutional Review Boards, and informed consent was provided by
all study participants. The study was conducted according to the
Declaration of Helsinki Principles.
LOH analysis
Tumor DNA was extracted from diagnostic specimens obtained from
the treating pathologist or pathology laboratory. Three 20-mm
sections from the paraffin block were cut and placed in an Eppendorf
tube. Paraffin was dissolved using Histochoice Clearing Agent
(Sigma-Aldrich, St Louis, MO), followed by two washes with 100%
ethanol and one wash with phosphate-buffered saline. Samples were
incubated overnight in SDS-lysis solution and proteinase K (Qiagen,
Valencia, CA), at 551C. De-crosslinking was achieved by incubation
with NaCl at a final concentration of 0.7 M, and DNA recovered
using the Wizard DNA clean-up kit (Promega, Madison, WI).
Corresponding peripheral blood DNA was isolated for each case
(Qiagen).
Five microsatellite loci, D9S15, D9S53, D9S196, D9S176,
including an intragenic microsatellite in PTCH (exon 1a, 1AJL;
Louhelainen et al., 1998) were examined. Fluorescent dye labeled
primer pairs for each locus were obtained from Research Genetic’s
Map Pair list (Invitrogen, Carlsbad, CA). Each PCR mixture contained
1.5 ml of template DNA, 12.5 pmol of each primer, 0.2 mM
deoxynucleoside triphosphates, 1 ml of 10 reaction buffer, and
1.25 units of AmpliTaqGold (Applied Biosystems, Foster City, CA) in
a final volume of 12.5 ml. Reaction conditions were as described by
Shen et al. (1999), with varying annealing temperatures for each loci
being studied. Briefly, 40 cycles of amplification were performed:
941C for 40 seconds, annealing at 55–641C (depending on primer set)
for 1 minute and extension at 721C for 1 minute. A final extension
was done for 10 minutes. Amplified PCR products were run on a 4%
denaturing polyacrylamide gel for ABI PRISM 377 (Applied
Biosystems) with a labeled marker (TAMRA 350) as an internal size
standard. The data were analyzed with the Genescan 2.1 software
(Applied Biosystems). For each informative locus, the allelic ratio
was calculated using the peak heights from the blood and tumor-
derived DNA samples. LOH was determined by dividing the allelic
ratio in the blood-derived DNA by the allelic ratio in the tumor-
derived DNA. Ratios of o0.5 or 41.5 were scored as positive for
LOH.
Statistical analysis
Determinants of LOH were investigated using univariate (w2 and
Wilcoxon’s rank-sum test) and multivariate methods. Odds ratios
were calculated using unconditional logistic regression. All statis-
tical analyses were performed using the SAS software system and all
statistical tests were two-sided.
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